Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
Sun Pharmaceutical Industries Ltd announces in a media release that one of its wholly owned subsidiaries presented further evidence of the long-term use and cost-effectiveness of ILUMYA (tildrakizumab-asmn) in moderate-to-severe plaque psoriasis at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020.
